Auna Announces 2Q24 Financial Results
Auna (NYSE: AUNA), a leading healthcare platform in Latin America, announced strong Q2 2024 financial results. Consolidated revenue increased 18% YoY to S/1,120 million, while Adjusted EBITDA rose 31% YoY to S/248 million. The company's Adjusted EBITDA margin expanded to 22.1%, up 2.0 percentage points YoY. Auna's leverage ratio improved to 4.13x from 4.89x in Q2 2023.
Key highlights include:
- Operating profit increased 34% YoY to S/183 million
- Net Income of S/8 million, compared to a Net loss of S/8 million in Q1 2024
- Launch of OncoMexico, the country's first integrated oncology insurance, in Monterrey
Auna's Executive Chairman emphasized the effectiveness of their business model and the company's progress in implementing the AunaWay in Monterrey. The company remains confident in achieving at least 20% FXN Adjusted EBITDA growth for the year.
Auna (NYSE: AUNA), una delle principali piattaforme sanitarie in America Latina, ha annunciato risultati finanziari solidi per il secondo trimestre del 2024. Il fatturato consolidato è aumentato del 18% su base annuale, raggiungendo S/1.120 milioni, mentre l'EBITDA rettificato è aumentato del 31% su base annuale, raggiungendo S/248 milioni. Il margine EBITDA rettificato dell'azienda si è ampliato al 22,1%, con un incremento di 2,0 punti percentuali rispetto all'anno precedente. Il rapporto di indebitamento di Auna è migliorato a 4,13x, rispetto a 4,89x nel secondo trimestre del 2023.
I punti salienti includono:
- Il profitto operativo è aumentato del 34% su base annuale, raggiungendo S/183 milioni
- Il reddito netto è stato di S/8 milioni, rispetto a una perdita netta di S/8 milioni nel primo trimestre del 2024
- Il lancio di OncoMexico, il primo assicurazione oncologica integrata del paese, a Monterrey
Il presidente esecutivo di Auna ha sottolineato l'efficacia del loro modello di business e i progressi dell'azienda nell'implementazione del AunaWay a Monterrey. L'azienda rimane fiduciosa di raggiungere almeno il 20% di crescita dell'EBITDA rettificato in valuta costante per l'anno.
Auna (NYSE: AUNA), una de las principales plataformas de salud en América Latina, anunció resultados financieros sólidos para el segundo trimestre de 2024. Los ingresos consolidados aumentaron un 18% interanual, alcanzando S/1,120 millones, mientras que el EBITDA ajustado creció un 31% interanual, sumando S/248 millones. El margen de EBITDA ajustado de la compañía se expandió al 22.1%, un aumento de 2.0 puntos porcentuales interanuales. La razón de apalancamiento de Auna mejoró a 4.13x desde 4.89x en el segundo trimestre de 2023.
Los aspectos destacados incluyen:
- El beneficio operativo creció un 34% interanual, alcanzando S/183 millones
- El ingreso neto fue de S/8 millones, en comparación con una pérdida neta de S/8 millones en el primer trimestre de 2024
- Lanzamiento de OncoMexico, el primer seguro de oncología integrado del país, en Monterrey
El presidente ejecutivo de Auna enfatizó la efectividad de su modelo de negocio y los progresos de la compañía en la implementación del AunaWay en Monterrey. La empresa se mantiene confiada en alcanzar al menos un crecimiento del 20% en EBITDA ajustado en moneda constante para este año.
Auna (NYSE: AUNA)는 라틴 아메리카의 주요 헬스케어 플랫폼으로서 2024년 2분기 강력한 재무 실적을 발표했습니다. 총 매출은 전년 대비 18% 증가하여 S/1,120 백만에 달했습니다, 조정된 EBITDA는 전년 대비 31% 증가하여 S/248 백만에 이릅니다. 회사의 조정된 EBITDA 마진은 22.1%로 확대되어 전년 대비 2.0% 포인트 증가했습니다. Auna의 레버리지 비율은 2023년 2분기의 4.89x에서 4.13x로 개선되었습니다.
주요 하이라이트는 다음과 같습니다:
- 운영 이익은 전년 대비 34% 증가하여 S/183 백만에 이릅니다
- 순이익은 S/8 백만으로, 2024년 1분기에는 S/8 백만의 순손실을 기록했습니다
- 몬테레이에 국가 최초의 통합 종양 보험인 OncoMexico 출시
Auna의 이사회 의장은 비즈니스 모델의 효과성과 몬테레이에 있는 AunaWay 구현에서 회사의 진전을 강조했습니다. 회사는 올해 20% 이상의 FXN 조정 EBITDA 성장을 달성할 수 있다고 확신하고 있습니다.
Auna (NYSE: AUNA), une plateforme de santé leader en Amérique latine, a annoncé de solides résultats financiers pour le deuxième trimestre 2024. Le chiffre d'affaires consolidé a augmenté de 18% d'une année sur l'autre pour atteindre 1,120 million de S/, tandis que l'EBITDA ajusté a augmenté de 31% d'une année sur l'autre, atteignant 248 millions de S/. La marge EBITDA ajustée de l'entreprise s'est élargie à 22,1%, avec une augmentation de 2,0 points de pourcentage par rapport à l'année précédente. Le ratio d'endettement d'Auna s'est amélioré à 4,13x contre 4,89x au deuxième trimestre 2023.
Les points clés comprennent :
- Le bénéfice opérationnel a augmenté de 34% d'une année sur l'autre pour atteindre 183 millions de S/
- Le revenu net était de 8 millions de S/, comparé à une perte nette de 8 millions de S/ au premier trimestre 2024
- Lancement d'OncoMexico, le premier contrat d'assurance oncologique intégré du pays, à Monterrey
Le président exécutif d'Auna a souligné l'efficacité de leur modèle commercial et les progrès réalisés par l'entreprise dans la mise en œuvre de l'AunaWay à Monterrey. L'entreprise reste confiante quant à l'atteinte d'une croissance d'au moins 20% de l'EBITDA ajusté en monnaie constante pour l'année.
Auna (NYSE: AUNA), eine führende Gesundheitsplattform in Lateinamerika, hat starke Finanzzahlen für das zweite Quartal 2024 bekannt gegeben. Der konsolidierte Umsatz stieg im Jahresvergleich um 18% auf S/1.120 Millionen, während das bereinigte EBITDA um 31% im Jahresvergleich auf S/248 Millionen anstieg. Die EBITDA-Marge des Unternehmens erweiterte sich auf 22,1%, was einen Anstieg von 2,0 Prozentpunkten im Jahresvergleich bedeutet. Das Verschuldungsverhältnis von Auna verbesserte sich auf 4,13x von 4,89x im zweiten Quartal 2023.
Wichtige Höhepunkte sind:
- Der Betriebsgewinn stieg um 34% im Jahresvergleich auf S/183 Millionen
- Der Nettogewinn betrug S/8 Millionen, verglichen mit einem Nettoverlust von S/8 Millionen im ersten Quartal 2024
- Einführung von OncoMexico, der ersten integrierten Onkologieversicherung des Landes, in Monterrey
Der Executive Chairman von Auna betonte die Effektivität ihres Geschäftsmodells und den Fortschritt des Unternehmens bei der Umsetzung von AunaWay in Monterrey. Das Unternehmen ist zuversichtlich, in diesem Jahr mindestens 20% Wachstum des FXN bereinigten EBITDA zu erreichen.
- Consolidated revenue increased 18% YoY to S/1,120 million
- Adjusted EBITDA rose 31% YoY to S/248 million
- Operating profit increased 34% YoY to S/183 million
- Adjusted EBITDA margin expanded to 22.1%, up 2.0 percentage points YoY
- Leverage ratio improved to 4.13x from 4.89x in Q2 2023
- Successful launch of OncoMexico, the first integrated oncology insurance in Mexico
- Net Income decreased to S/8 million in Q2 2024 from S/23 million in Q2 2023
- Negative non-cash accounting FX expense of S/49 million due to Peruvian Sol movement
- Adjusted Net Income decreased to S/13 million from S/36 million in Q2 2023
Insights
Auna's Q2 2024 results demonstrate strong financial performance, with key metrics showing significant year-over-year growth. Consolidated revenue increased 18% YoY to
The company's leverage ratio improved to 4.13x from 4.89x in Q2 2023, suggesting better debt management. However, net income decreased to
The launch of OncoMexico represents a strategic move to replicate Auna's successful vertically integrated healthcare model in a new market, potentially driving future growth. Overall, these results indicate Auna is on track to meet its
Auna's Q2 2024 results reflect the company's successful expansion and operational strategy in Latin America's healthcare market. The 18% YoY revenue growth and 31% YoY Adjusted EBITDA increase demonstrate the scalability of Auna's business model across different regions.
The launch of OncoMexico in Monterrey is a significant development. As the first integrated oncology insurance in Mexico, it addresses a critical healthcare need, with cancer being the third leading cause of death in the country. This move leverages Auna's 35 years of experience in oncological services and could be a game-changer in the Mexican healthcare landscape.
The company's focus on high-complexity care and physician recruitment in Monterrey shows a strategic approach to market penetration. By replicating its successful model from Peru and Colombia, Auna is positioning itself as a disruptor in the fragmented Latin American healthcare market. The gradual implementation of the AunaWay in Mexico, while initially impacting short-term metrics, could lead to substantial long-term growth and market share gains.
Adjusted EBITDA increases
OncoMexico launched in Monterrey
LUXEMBOURG--(BUSINESS WIRE)--
Auna (NYSE: AUNA) (“Auna” or the “Company”), a leading healthcare platform in
2Q24 Consolidated Highlights
-
Consolidated Revenue increased
18% YoY to S/1,120 million -
Operating profit increased
34% YoY to S/183 million -
Adjusted EBITDA increased
31% YoY to S/248 million, equivalent to25% FXN (Foreign Exchange Neutral) -
Adjusted EBITDA Margin of
22.1% , up 2.0 p.p. YoY and 0.5 p.p. YTD - Leverage ratio improved to 4.13x from 4.46x in 1Q24 and 4.89x in 2Q23
Recent Event
On July 1, 2024, Auna announced the launch of OncoMexico, the country’s first integrated oncology insurance, in Monterrey. The pilot phase during 2024 will develop and confirm the capabilities needed for full deployment in 2025. OncoMexico offers access to prevention, early detection, and treatment of cancer, the third leading cause of death in
Message from Auna’s Executive Chairman and President
Second quarter results affirm again the effectiveness of our business model and how increased scale and maturity drive incremental value throughout our platforms of care. During the quarter we gained momentum, with Adjusted EBITDA increasing
Both our Peruvian and Colombian operations continued to perform well during the quarter, further validating our scalable business model and growth strategy. Given the increasing predictability of our diversified regional platform’s performance, we remain confident in our plan to achieve similar performance levels in
Our payors are also integral to succeeding in
We are very proud to have launched OncoMexico. Leveraging our 35 years of experience in integrated oncological services and AunaSeguros’ (previously Dentegra) strong and extensive distribution platform in
Looking ahead, we remain excited about Auna’s near and long-term growth opportunities, particularly given that we are in the relatively early stages of penetrating Spanish-speaking Latin America’s fragmented and underserved healthcare market. Through our unique operating model and scalable regional platform, we will continue to disrupt, modernize, and increase access to integrated healthcare in the region, always with the aim of providing high value to our patients, their families, Auna staff, and shareholders.
Overview of 2Q24 Consolidated Results
Consolidated revenues increased
Auna’s Peruvian operation continues to outperform, demonstrating again the success of the Company’s vertically integrated business model when operating at scale.
Adjusted EBITDA increased
Net finance costs were S/182 million. When excluding FX effects, net interest expenses would have been S/133 million, an increase of
Net Income was S/8 million in 2Q24, compared to a Net loss of S/8 million in 1Q24 and Net income of S/23 million in 2Q23. The increases in Operating profit and deferred tax benefits versus 2Q23 were offset by the abovementioned negative FX effect.
Adjusted Net Income was S/13 million in 2Q24, lower than S/36 million in 2Q23 and S/22 million in 1Q24, mainly due to the negative non-cash FX effect explained above. On a quarterly per share basis, Auna reported Net Income of S/0.05 and Adjusted Net Income of S/0.12, both based on a weighted average number of outstanding shares of 73,970,299, which includes a stock-based payment for 52,722 shares granted but not yet issued.
For a full version of AUNA’s Second Quarter 2024 Earnings Release, please visit: https://aunainvestors.com/English/financial-information/quarterly-results/
Conference Call Details
When: 5:00 p.m. Eastern time, August 21st, 2024
Who: Mr. Suso Zamora, Executive Chairman of the Board and President; Mrs. Gisele Remy, Chief Financial Officer and Executive Vice President; Ms. Ana Maria Mora, Head of Investor Relations
Dial-in: +1 888 596 4144 (
Passcode: 3884034
To access Auna′s financial results call via telephone, callers need to press # to be connected to an operator.
Webcast: click here
Safe Harbor Statement
This press release contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to differ materially from the forward-looking statements that we make. Forward-looking statements typically are identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” ”estimate,” “intend,” “project,” “plan,” “believe,” “potential,” “continue,” “is/are likely to, ”or other similar expressions. Forward-looking statements that appear in a number of places in this press release include, but are not limited to, statements regarding the intent, belief or current expectations, regarding various matters, including, our expected 2024 Adjusted EBITDA growth, the expected impact on revenues and profitability of certain initiatives we are pursuing in
The forward-looking statements in this press release represent our expectations and forecasts as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. For a discussion of the risks facing the Company which could affect whether these forward-looking statements are realized, see our Form F-1 filing with the
2024 Financial Guidance Disclaimer
Auna′s guidance is based on management’s current performance outlook and expected macroeconomic and regulatory conditions in the three countries where the Company operates. Any changes in these conditions could have an impact on the guidance provided.
The 2024 financial guidance reflects management’s current assumptions regarding numerous evolving factors that are difficult to accurately predict, including those discussed in the Risk Factors set forth in the Company’s Form F-1 filed with the United States Securities and Exchange Commission (the “SEC”). Reconciliations of forward-looking non-IFRS measures, specifically the 2024 EBITDA guidance, to the relevant forward-looking IFRS measures are not being provided, as the Company does not currently have sufficient data to accurately estimate the variables and individual adjustments for such guidance and reconciliations. Due to this uncertainty, the Company cannot reconcile projected EBITDA to projected net income without unreasonable effort. The 2024 financial guidance constitutes forward-looking statements. For more information, see the “Forward-Looking Statements” section in this release.
About AUNA
Auna is a leading healthcare platform in Latin American healthcare company with operations in
For more information visit www.aunainvestors.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821215904/en/
IR Contact
Email: contact@aunainvestors.com
Source: Auna S.A.
FAQ
What was Auna's revenue growth in Q2 2024?
How much did Auna's Adjusted EBITDA grow in Q2 2024?
What was Auna's (AUNA) Adjusted EBITDA margin in Q2 2024?
What new product did Auna launch in Mexico in July 2024?
How did Auna's leverage ratio change in Q2 2024?
